Evidence map›Paper›PMID 36365216›Full record

ArticlePharmaceutics2022

Itraconazole Amorphous Solid Dispersion Tablets: Formulation and Compaction Process Optimization Using Quality by Design Principles and Tools.

Hetvi Triboandas, Kendal Pitt, Mariana Bezerra, Delphine Ach-Hubert, Walkiria Schlindwein

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Co-amorphization for solubility and dissolution rate improvement: the case of low-crystallization-tendency drugs.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Hetvi TriboandasLeicester School of Pharmacy, De Montfort University, Leicester LE1 9BH, UK.
Kendal PittLeicester School of Pharmacy, De Montfort University, Leicester LE1 9BH, UK.
Mariana BezerraLeicester School of Pharmacy, De Montfort University, Leicester LE1 9BH, UK.
Delphine Ach-HubertMedelpharm, 615 rue du Chat Botté, ZAC des Malettes, F-01700 Beynost, France.
Walkiria SchlindweinLeicester School of Pharmacy, De Montfort University, Leicester LE1 9BH, UK.
De Montfort University · GBAmer Sports (France) · FR

Funding

De Monftfort University PhD scholarship
6 · The paper itself

Abstract

BCS Class II drugs, such as itraconazole (ITZ), exhibit poor solubility (1-4 ng/mL) and so require solubility enhancement. Therefore, ITZ and Kollidon

Indexed as

amorphous solid dispersion (ASD)hot-melt extrusion (HME)itraconazole (ITZ)quality by design (QbD)solubility enhancementtablet compaction

Identifiers

PMID36365216
PMCPMC9693276
OpenAlexW4308506804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.